The role of insomnia in the treatment of chronic fatigue  by Kallestad, Håvard et al.
Journal of Psychosomatic Research 78 (2015) 427–432
Contents lists available at ScienceDirect
Journal of Psychosomatic ResearchThe role of insomnia in the treatment of chronic fatigueHåvard Kallestad a,b,⁎, Henrik B. Jacobsen c,d,e, Nils Inge Landrø c,e,f, Petter C. Borchgrevink c,d,e, Tore C. Stiles d,f,g
a Norwegian University of Science and Technology, Department of Neuroscience, Trondheim, Norway
b St. Olav's University Hospital, Department of Østmarka, Trondheim, Norway
c St. Olav's University Hospital, Hysnes Rehabilitation Center, Trondheim, Norway
d St. Olav's University Hospital, National Competence Center for Pain and Complex Disorders, Trondheim, Norway
e Norwegian University of Science and Technology, Department of Circulation and Medical Imaging, Trondheim, Norway
f University of Oslo, Department of Psychology, Oslo, Norway
g Norwegian University of Science and Technology, Department of Psychology, Trondheim, Norway⁎ Corresponding author at: Håvard Kallestad Norwe
Technology, Department of Neuroscience, Medisinsk T
Trondheim Norway.
E-mail address: havard.kallestad@ntnu.no (H. Kallesta
http://dx.doi.org/10.1016/j.jpsychores.2014.11.022
0022-3999/© 2014 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 21 August 2014
Received in revised form 26 November 2014
Accepted 30 November 2014
Keywords:
Fatigue
Insomnia
Cognitive therapy
Stress
Background: The deﬁnition of Chronic Fatigue Syndrome (CFS) overlaps with deﬁnitions of insomnia, but there is
limited knowledge about the role of insomnia in the treatment of chronic fatigue.
Aims: To test if improvement of insomnia during treatment of chronic fatiguewas associatedwith improved out-
comes on 1) fatigue and 2) cortisol recovery span during a standardized stress exposure.
Methods: Patients (n = 122) with chronic fatigue received a 3.5-week inpatient return-to-work rehabilitation
program based on Acceptance and Commitment Therapy, and had been on paid sick leave N 8 weeks due their
condition. A physician and a psychologist examined the patients, assessedmedication use, and SCID-I diagnoses.
Patients completed self-report questionnaires measuring fatigue, pain, depression, anxiety, and insomnia before
and after treatment. A subgroup (n= 25) also completed the Trier Social Stress Test for Groups (TSST-G) before
and after treatment. Seven cortisol samples were collected during each test and cortisol spans for the TSST-G
were calculated.
Results: A hierarchical regression analysis in nine steps showed that insomnia improvement predicted improve-
ment in fatigue, independently of age, gender, improvement in pain intensity, depression and anxiety. A second
hierarchical regression analysis showed that improvement in insomnia signiﬁcantly predicted the cortisol recov-
ery span after the TSST-G independently of improvement in fatigue.
Conclusion: Improvement in insomnia severity had a signiﬁcant impact on both improvement in fatigue and the
ability to recover from a stressful situation. Insomnia severity may be a maintaining factor in chronic fatigue and
speciﬁcally targeting this in treatment could increase treatment response.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Chronic Fatigue Syndrome (CFS) is a condition primarily character-
ized by persistent and profound fatigue of at least six months duration
(1). It causes substantial disruption to the individual's daily function.
The fatiguehas to be unexplained andnot the result of ongoing exertion,
and not substantially alleviated by rest. In addition to fatigue, the diag-
nostic criteria require the concurrence of four or more of the following
symptoms: muscle- and joint-pain, headache, sore throat, impairment
in memory or concentration, unrefreshing sleep, and postexertional
fatigue lasting more than 24 h. The prevalence rates for CFS vary de-
pending on the deﬁnition and the criteria used. Community andgian University of Science and
eknisk Forskningssenter, 7489
d).
. This is an open access article underprimary care studies have reported the prevalence to be between 0.2%
and 2.6% (2).
Cognitive Behavior Therapy (CBT) has been shown to be an effective
treatment of CFS (3). A meta-analysis of 1371 patients in 13 studies
found that the mean between-group effect size for CBT compared to
placebo was d= 0.48, which corresponds to a medium effect size. Al-
though these are promising results, there is still room for improvement.
It is therefore important to better understand the maintaining factors
involved in CFS that could be potential therapeutic targets.
One factor that could be involved in the maintenance of CFS is in-
somnia. Insomnia can be deﬁned as the subjective experience of dis-
turbed or non-restorative sleep that gives rise to daytime impairment
despite adequate opportunity and circumstances for sleep (4,5). Despite
its high prevalence, insomnia is often overlooked in clinical settings (6),
and it is underdiagnosed in patients with CFS (7).
CFS and insomnia have overlapping features. Between 87% and
95% of patients meeting criteria for CFS report non-restorative orthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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insomnia (5,9). Like in insomnia, CFS is more associatedwith subjective
experience of sleep disturbance rather than objective measures of poor
sleep (10). Impairment in memory or concentration is a symptom of
both insomnia and of CFS (1,5). It is possible that a proportion of the fa-
tigue CFS patients experience may be related to poor sleep quality and
insomnia, whereas others have suggested that insomnia symptoms in
CFS are secondary to pain and depression (11).
Adaptive response to stress could be a common factor between in-
somnia and CFS. Sleep is important to restore the capacity to regulate
emotions when exposed to negative stimuli (8,12) and could have a
stress-buffering effect (13). In CFS, the ability to recover after a stressor
is impaired (14) and stress exacerbates the symptomsof fatigue (15). At
a physiological level, CFS patients display a ﬂattened cortisol variation
when exposed to a naturalistic stressor such as awakening (16) or in
laboratorywith the Trier Social Stress Task (TSST) (17). This low cortisol
variability has been claimed to be a physiological expression of vital ex-
haustion, a mental state where the ability to adapt to stress is disrupted
(18,19) and one of the biological factors contributing to the mainte-
nance of CFS (16). Interestingly, a ﬂattened response on the TSST has
also been found to be a consequence of poor sleep quality (13). The au-
thors of this study suggested that the stress-buffering effect of sleep is
associated with improved parasympathetic tone and normalized corti-
sol patterns during the day (13). Improvement in insomnia severity
during treatment could therefore contribute to normalizing cortisol pat-
terns for patients with CFS. Repeated standardized stress exposures,
such as the TSST before and after treatment, has been argued as an
ideal study design for the investigation of such treatment effects (20).
The overarching aim of this study was to examine a possible role of
insomnia in the treatment of chronic fatigue. All patients were treated
for chronic fatiguewith a 3.5-week intensive return-to-work (RTW) re-
habilitation program based on Acceptance and Commitment Therapy
(ACT) (21). Speciﬁcally, our hypotheses were that 1) improvement in
insomnia severity during treatment would predict lower levels of
fatigue at treatment termination when controlling for the possible con-
founding effects of pain intensity, depression, and anxiety. 2) Improve-
ment in insomnia severity during treatment would predict increased
changes in the cortisol recovery span on the Trier Social Stress Test for
Groups (TSST-G) from pre to post treatment over and above the effects
of fatigue improvement.
Method
Setting
This was a repeated measures treatment study with participants
being consecutively recruited from January 2012 to June 2013 to a 3.5-
week occupational rehabilitation program at Hysnes Occupational Re-
habilitation Center at St. Olav's University Hospital in Trondheim,
Norway.
Prior to the enrolment, the patients had all been referred from their
general practitioner and thereafter examined and selected by an outpa-
tient multidisciplinary team at St. Olav's University Hospital consisting
of a physician, a psychologist, and a physiotherapist. This team evaluat-
edwhether the referred patientsmet the requirements for participating
in the RTW-program, which were the same as the inclusion and exclu-
sion criteria for the study. Before being evaluated at the outpatient clin-
ic, all patients were asked to complete 18 different questionnaires (386
items) through an online self-report survey. At the end of the program
and the study, the patients again completed six of these questionnaires
online.
Patients
The study population consisted of patients on long-term sick leave
who upon inclusion to the program gave their informed consent tojoin the study. The inclusion criteria were age between 18 and 60
years and to have been on sick leave for at least eightweeks due tomus-
culoskeletal disorders, pain, fatigue and/or common mental disorders.
Further they should have self-deﬁned goals of increasing labor partici-
pation, to be adequately assessed and treated beforehand for any specif-
ic health problems, and be able to attend a rehabilitation program from
8:30 to 3:00 p.m. all weekdays.
The exclusion criteria were severe mental illness (ongoing mania,
psychosis or suicidal ideation), substance abuse and addiction, pregnan-
cy, and unexpressed difﬁculty functioning in a group. Moreover,
patients who could not communicate in Norwegian or who needed
24-hour personal assistance were not accepted for rehabilitation. In ad-
dition to the inclusion criteria in the RTW program, the patients in the
current study had to report fatigue for more than six months and
score 5 or above on the Chalder Fatigue Scale (22). According to Chalder
et al. (22) a score above 5 may be considered a case of chronic fatigue.
Moreover, to be included in all the planned steps of analyses, the pa-
tients could not have anymissing data on any of the covariates targeted
in the subsequentmultivariable analysis. The patientswere a subsample
from larger clinical trial (21).
Twenty-ﬁve of these patients were selected using a list randomiza-
tion as described in another study (18). They were administered the
Trier Social Stress Test for Groups (TSST-G) before and after treatment.
The subgroup was included in the analyses to test our secondary
hypothesis.
Treatment
A rehabilitation program designed to increase return-to-work was
used as a multidisciplinary inpatient intervention with ACT as an over-
arching treatmentmodel. Details on the rehabilitation programare pub-
lished elsewhere (21). The program was group-based with up to eight
participants in each group. However, the program used both group-
based and individual approaches to facilitate rehabilitation. It was orga-
nized through seven-hourworkdays and lasted 17workdays. The group
sessions included socialization to the ACTmodel andmotivating the pa-
tient for change, barriers and the issue of control, consequences of
attempting to control the symptoms, family and important supporters,
cognitive defusion (you are not your thoughts), communication and
conﬂict, language and staying committed to value-guided behavior. In
the individual sessions the focus was on identifying the patient's goals
and values, and helping the patients commit to his/her chosen values.
The therapists were coined return-to-work coordinators, trained
and supervised in ACT, and targeted three areas of rehabilitation: men-
tal training, physical training and work-related problem solving. The
teamof coordinators had extensive and diverse backgrounds (e.g. phys-
ical therapy, psychology, exercise physiology, medicine, nursing), and
each coordinator was responsible for mentoring two or three partici-
pants through the program. There were three multidisciplinary team
meetings during the inpatient stay where the coordinators discussed
possible strategies for handling the participants' obstacles and possibil-
ities with regard to returning to work.
Assessments
Psychological and medical examination
A licensed clinical psychologist assessed the presence of comorbid
mental disorders using the Structured Clinical Interview for DSM-IV
(SCID-I) (23). A physician reviewed the participants' medical records
and assessed current medication.
Fatigue
The Chalder Fatigue Scale was used to assess levels of fatigue (22). It
is an 11-item self-report questionnaire assessing bothmental and phys-
ical fatigue. Each item has four response categories scored bimodally 0–
0–1–1. (e.g., 0 = better than usual; 0= nomore than usual; 1=worse
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indicates chronic fatigue, lasting for six months or more. This question-
naire has been shown to be highly reliable and valid (22).
Pain
To assess level of pain, one item from the Short Form-8 (SF-8) de-
scribing average pain intensity the last 7 days on a 6-point Likert scale
from 1 = no pain to 6 = very strong pain was used (24). This item
has been validated as a self-report measure of pain in a large Norwegian
cohort (25).
Depression and anxiety
The Hospital Depression and Anxiety Scale (HADS) was used to as-
sess the levels of depression and anxiety. The HADS is a 14-item self-
report questionnaire with 7 items describing depressive symptoms
and 7 items describing anxiety symptoms (26,27) and has been found
to be valid for use in patients with Chronic Fatigue (28).
Insomnia
The Insomnia Severity Index (ISI) was used to assess the levels of
insomnia symptoms (29). The ISI is a seven-item self-report question-
nairemeasuring the nature, severity and impact of insomnia symptoms
the past twoweeks. The items are: 1) difﬁculty falling asleep, 2) difﬁcul-
ty maintaining sleep, 3) early morning awakenings, 4) satisfaction/
dissatisfaction with sleep pattern, 5) interference of sleep problems
with daily functioning, 6) sleep problems being noticeable by others
and 7) levels of distress/worry caused by the sleep problems. Each
item is rated by using a 5-point Likert scale (e.g., 0 = no problem;
4 = very severe problem) giving a total score ranging from 0 to 28.
The ISI has shown to have very good reliability and validity (29,30)
and is recommended as an outcomemeasure for insomnia in clinical tri-
als (31).
Trier Social Stress Test for Groups (TSST-G)
A subgroup of patients were administered the TSST-G before and
after treatment. The TSST-G, as described in von Dawans et al. (32),
was used to create psychosocial stress among the participants. The
TSST-G is an experimental test designed to trigger mental stress
among participants under controlled conditions. TSST-G is a perfor-
mance task consisting of high levels of socio-evaluative threat and un-
controllability in a group format. The test consists of a preparation
phase where the patients are instructed to prepare an application for a
job of their choice in front of an expert panel. The exposure phase is a
public speaking task (mock job interview) and mental arithmetic task
(serial subtraction) in front of a panel of two evaluators. A recovery
phase then follows where the patients are given an opportunity to
share thoughts and reﬂections considering the experience. Each session
lasts approximately 2.5 h including the 50 min preparation phase,
30 min exposure phase and 60 min recovery phase. Both pre-
treatment and post-treatment sessions took place between 14:30 h,
16:30 h and/or 19:30 h in order to control for diurnal variation in corti-
sol secretion. These timeslots have been validatedwith regard to diurnal
variation in previous studies (33).
Cortisol sampling
Seven saliva samples were collected during the TSST-G. One was
taken during the preparation period, two during the experiment, and
four were taken during the recovery phase. Purpose-designed polyester
salivettes produced by Sarstedt Inc., Rommelsdorf, Germany, were used
to collect the samples and have been used in several previous studies
(32,34). After sampling the salivettes were stored at −20 °C before
being analyzed at the Department of Medical Biochemistry at St. Olavs
Hospital, Trondheim. The samples were thawed, centrifuged and ana-
lyzed onModular E170 from Roche using an electrochemiluminescence
immunoassay (ECLIA)method. The assay used for determination of cor-
tisol in saliva had an interassay variability of 7.9% at 12 nmol/L.Cortisol recovery after the TSST-G
In the current experiment, we studied the cortisol change from im-
mediately after the exposure phase until the end of the recovery
phase. That is, we assessed the change in cortisol levels in the fourth sa-
liva sample and the seventh saliva sample as a measure of how the pa-
tients recovered from the exposure phase. This was calculated for the
pre-treatment TSST-G and the post-treatment TSST-G. A variable de-
scribing the pre to post treatment change in cortisol recovery span
after the TSST-G was then calculated as described in previous studies
(35). This variable was used in the statistical analysis.
Autonomic and psychological stress response
Continuous recording of heart rate was measured using a wireless
chest heart rate transmitter and a wristwatch recorder (Polar
RS800TS, Polar Electro, Finland). This was used as a measure of task en-
gagement and sympathetic arousal. Additionally, the participants com-
pleted Visual Analog Scales (VAS) 10min before, and 3 times during the
exposure phase of the TSST-G on the domains of avoidance, anxiety, and
tension. A previous study from the same patient sample found that
changes in heart rate and VAS scales during the test conﬁrmed substan-
tial autonomic and psychological activation (17).
Ethics
The study was approved by the Regional Ethical Committee for Re-
search in Health in Trondheim, Norway.
Statistics
A cut-off of ISI N 14 was used to determine patients with clinically
signiﬁcant insomnia symptoms and a cut-off of ISI b 8was used to deter-
mine patients who were normal sleepers.
To test if there was a difference before and after treatment on the in-
cluded variables, we conducted paired samples t-tests. Cohen's effect
sizes were calculated using the equation (mpost−mpre)/SDpooled.
In order to test the hypothesis that improvement in insomnia sever-
ity during treatment would predict lower levels of fatigue at treatment
termination, independently of changes in pain, depression and anxiety,
we conducted a hierarchical regression analysis in 9 steps. The depen-
dent variable was level of fatigue post treatment. In step 1 we entered
age, in step 2 we entered gender, in step 3 we entered level of fatigue
pre treatment, in step 4 we entered pain intensity pre treatment, in
step 5 we entered level of depression and anxiety pre treatment, in
step 6 we entered level of insomnia severity pre treatment, in step 7
we entered level of pain intensity post treatment, in step 8 we entered
levels of depression and anxiety post treatment, and in step 9 we en-
tered level of insomnia severity post treatment. When entering the in-
dependent variables in this order, the regression model tests how
improvement from pre to post therapy in pain, depression and anxiety,
and insomnia severity predicts improvement in levels of fatigue, inde-
pendently of level of the variables entered previously in the regression
analysis.
In order to test the hypothesis that insomnia improvement will in-
crease changes in the cortisol recovery span from pre to post treatment,
over and above the effects of reduction in levels of fatigue, we conduct-
ed another hierarchical regression analysis in two steps. The dependent
variable was the pre to post treatment change in the cortisol recovery
after the TSST-G. Because patients have a ﬂattened cortisol response
pre treatment, a negative value will represent a favorable outcome
where the cortisol recovery is larger after treatment than pre treatment.
In step 1 we entered change in fatigue from pre to post treatment. In
step 2 we entered change in insomnia severity from pre to post treat-
ment. We used change variables in this analysis rather than pre and
post therapy variables because the number of patients was limited.
Because it is possible that the change in cortisol recovery is a marker
of how stressed the patients initially become in the test, rather than
Table 2
Summaryof thehierarchical regression analysis on predictors of level of fatigue after treat-
ment for 122 patients with chronic pain. The regression model explains 34% of the total
variance in fatigue post treatment.
Step ΔR2 B SE
B
β t P
1 .04
Age .09 .04 .20 2.23 ⁎
2 .03
Age .08 .04 .19 2.20 ⁎
Gender 1.55 .85 .16 1.82
3 .11
Age .06 .04 .14 1.66
Gender 1.09 .81 .11 1.34
Fatigue pre treatment .70 .18 .34 3.95 ⁎⁎⁎
4 .01
Age .06 .04 .15 1.66
Gender 1.23 .82 .13 1.51
Fatigue pre treatment .75 .18 .37 4.18 ⁎⁎⁎
Pain pre treatment − .39 .28 − .12 −1.38
5 .00
Age .06 .04 .15 1.74
Gender 1.17 .82 .12 1.43
Fatigue pre treatment .79 .19 .38 4.22 ⁎⁎⁎
Pain pre treatment − .37 .28 − .12 −1.32
Depression and anxiety pre
treatment
− .03 .05 − .06 − .76
6 .00
Age .06 .04 .15 1.73
Gender 1.17 .82 .12 1.42
Fatigue pre treatment .79 .19 .38 4.18 ⁎⁎⁎
Pain pre treatment − .37 .29 − .12 −1.29
Depression and anxiety pre
treatment
− .04 .05 − .07 − .69
Insomnia pre treatment .00 .06 .00 .05
7 .01
Age .07 .04 .15 1.76
Gender 1.05 .83 .11 1.27
Fatigue pre treatment .79 .19 .38 4.19 ⁎⁎⁎
Pain pre treatment − .56 .34 − .18 −1.66
Depression and anxiety pre
treatment
− .03 .05 − .05 − .58
Insomnia pre treatment − .01 .06 − .01 .13
Pain post treatment .38 .35 .11 1.07
8 .09
Age .06 .04 .15 1.83
Gender 1.13 .79 .12 1.44
Fatigue pre treatment .88 .18 .43 4.88 ⁎⁎⁎
Pain pre treatment − .39 .33 − .12 −1.20
Depression and anxiety pre
treatment
− .17 .06 − .03 −2.74 ⁎⁎
Insomnia pre treatment − .02 .06 − .03 − .32
Pain post treatment − .02 .35 − .01 − .06
Depression and anxiety post
treatment
.25 .07 .40 3.72 ⁎⁎⁎
9 .10
Age .06 .03 .14 1.81
Gender 1.34 .74 .14 1.81
Fatigue pre treatment .90 .17 .44 5.34 ⁎⁎⁎
Pain pre treatment − .37 .30 − .11 −1.21
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analysis butwe also controlled for peak levels of cortisol after the stress-
or in step 1. In step 2 we entered improvement in fatigue, and in step 3
we entered improvement in insomnia.
Results
Descriptive data
A total of 279 patientswere offered treatment in the inclusion period, and 188 of these
patients reported chronic fatigue. Of the 188 patients with chronic fatigue, 144 patients
(76.7%) had complete datasets on all items before and after treatment. From the SCID in-
terview, a total of 22 patients (15.3%) were diagnosed with a comorbid mental disorder
before treatment. These 22 patients were excluded from the analyses in order to obtain
a pure sample of patients with chronic fatigue without comorbid mental disorders. The
ﬁnal sample for analyses was therefore 122 patients. These patients were between 22
and 61 years old and had a mean age of 44.0 (SD = 8.9). There were 98 females (80.3%)
and 24 males (19.7%)
Before treatment, 42 patients (34.4%) had clinically signiﬁcant insomnia symptoms,
whereas 23 patients (18.9%) had insomnia after treatment. Before treatment, 31 patients
(25.4%) were normal sleepers, whereas 51 patients (41.8%) were normal sleepers after
treatment.
See Table 1 for levels of fatigue, insomnia, pain, depression and anxiety before and
after treatment. There was a signiﬁcant improvement on all variables.
Hypothesis testing 1: Improvement in insomnia will predict improvement in fatigue over and
above the effects of improvement in pain, depression and anxiety
A summary of the hierarchical regression analysis testing predictors of fatigue post
treatment is shown in Table 2. The regression model explained 34% of the variance in
level of fatigue post treatment (Adjusted R2 = 0.34).
Improvement of painwas not associatedwith improvement in fatigue, as seen in step
7 of the regression analysis, whereas improvement in levels of depression and anxietywas
signiﬁcantly associated with improvement in fatigue as seen in step 8.
Improvement in insomnia severity, entered in the ﬁnal step, was signiﬁcantly associ-
ated with improvement in fatigue after controlling for age, gender, fatigue pre treatment,
improvement in pain, and improvement in depression and anxiety. Improvement in de-
pression and anxiety remained signiﬁcant in the ﬁnal step.
Hypothesis testing 2: Improvement in insomnia will predict improvement in cortisol recovery
over and above the effect of improvement in fatigue
A summary of the hierarchical regression analysis testing improvement in cortisol re-
covery is shown inTable 3. The regressionmodel explained 44% of the total variance in im-
provement in cortisol recovery.
Improvement in fatiguewas signiﬁcantly associated with improvement in cortisol re-
covery when entered in the ﬁrst step. Improvement in insomnia was signiﬁcantly associ-
ated with improvement in cortisol recovery when entered in the second step.
Improvement in fatigue remained signiﬁcant in the second step.
The results remained the same for the association between improvement of insomnia
and improvement in cortisol recovery when we conducted the regression analysis and
controlled for initial peak levels of cortisol.
Discussion
In this study we found that improvement in insomnia predicted
levels of fatigue post treatment in the treatment of patientswith chronic
fatigue. The results suggest that insomnia improvement has aTable 1
Changes in the clinical variables for 122 patients with chronic fatigue before and after 3.5
weeks of Acceptance and Commitment Therapy for chronic fatigue.
Variable Pre
treatment
Post
treatment
Paired samples t-test
Mean SD Mean SD t P d
Fatigue 8.97 1.86 5.62 3.83 10.3 b .001 1.11
Insomnia severity 12.0 6.07 9.51 6.12 5.55 b .001 0.41
Pain 3.96 1.20 3.50 1.15 4.71 b .001 0.39
Depression and anxiety 14.9 7.11 10.5 6.25 8.14 b .001 0.66
Fatigue = sum score on the Chalder Fatigue Scale.
Pain = score on level of somatic pain from the Short-Form 8.
Anxiety and depression = sum score on the Hospital Anxiety and Depression Scale.
Insomnia = sum score on the Insomnia Severity Index.
d= effect size, Cohen's d.
Depression and anxiety pre
treatment
− .12 .06 − .22 −2.07 ⁎
Insomnia pre treatment − .20 .07 − .32 −2.91 ⁎⁎⁎
Pain post treatment − .24 .33 − .07 − .71
Depression and anxiety post
treatment
.14 .07 .23 2.13 ⁎
Insomnia post treatment .30 .07 .48 4.21 ⁎⁎⁎
Dependent variable: sum score on the Chalder Fatigue Scale post treatment.
Fatigue = sum score on the Chalder Fatigue Scale.
Pain = score on level of somatic pain from the Short-Form Health Status-8.
Depression and anxiety = sum score on the Hospital Anxiety and Depression Scale.
Insomnia = sum score on the Insomnia Severity Index.
⁎ p = b0.05.
⁎⁎ p = b0.01.
⁎⁎⁎ p b 0.0001.
Table 3
Summary of the hierarchical regression analysis on predictors of improvement in cortisol
recovery span after the Trier Social Stress Test for Groups for a random subsample of 25
patients. The regression model explains 44% of the total variance in the improvement in
cortisol recovery span post treatment.
Step ΔR2 B SE
B
β t P
1 0.27
Fatigue reduction
during treatment
− .59 .19 − .53 −3.04 .006
2 0.17
Fatigue reduction
during treatment
− .42 .19 − .38 −2.28 .03
Insomnia reduction
during treatment
− .39 .15 − .43 −2.62 .02
Fatigue reduction = difference in the sum score on the Chalder Fatigue Scale before and
after treatment.
Insomnia reduction = difference in the sum score on the Insomnia Severity Index before
and after treatment.
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of improvements in pain, depression and anxiety. Moreover, we found
that this improvement in insomnia was strongly related to improved
stress response for these patients over and above the effects of im-
proved fatigue.
Research from the last decade on treatment of insomnia comorbid to
other disorders has shown that insomnia may be a useful therapeutic
target because improved insomnia can also enhance the effectiveness
of other treatments beyond the effects of improved sleep quality (e.g.
(36–39)). The present ﬁndings indicate that insomnia may have such
a function for patients with Chronic Fatigue Syndrome. This is particu-
larly interesting because the mean change on the insomnia severity
index was lower (d = 0.4) than what is typically found in treatment
studies using behavioral or cognitive behavioral therapy for insomnia
(d=2.0–2.5) (e.g. (40)). Thus, even amoderate change in insomnia se-
verity seemed to have a robust impact on outcomes.
The established ﬁrst line of treatment for insomnia is Cognitive Be-
havior Therapy for Insomnia (CBT-I) (41). One underlying assumption
of CBT-I is that spending excessive time in bed is one of themaintaining
factors of insomnia, and the core treatment component of sleep restric-
tion requires patients to curtail the time in bed to the time spent
sleeping (42). Patients with CFS may spend more time in bed than
other normal controls (8), which may maintain their insomnia symp-
toms. The treatment provided in the current study did not have a specif-
ic focus on insomnia. However, the structured inpatient treatment did
require patients to get up at the same time each morning regardless of
their sleep, have structured activities during the day, and spend less
time in bed than they usually do. The treatment did therefore include
some of the elements of CBT-I though not presented in the rationale
or structure of CBT-I. On the basis of these results it would be interesting
for future studies to test if providing concurrent CBT-I would enhance
the treatment outcomes for patients with CFS.
Impairment in theHPA-axis has been suggested as one of the biolog-
ical factors contributing to the maintenance in fatigue and other symp-
toms in CFS (16). We found that improvement in insomnia was related
to an improved cortisol recovery in response to a stressor. In the pres-
ence of CFS, this stress-buffering effect of sleep could be particularly im-
portant given that patientswith CFS report excessive fatigue in response
to stressors (15). Thus, improved sleep quality may improve the physi-
ological response to stress for these patients and could be a potential
mechanism of change in the treatment of CFS. Palesh et al. found that
sleep disruption was related to a ﬂattened cortisol response on the
TSST (43). Our result is in line with this, though we found that for pa-
tients who already displayed a ﬂattened cortisol response on the TSST,
improved insomnia severity is related to having improved cortisol re-
sponse. However, from the current study we do not know the direction
of causality. That is, we do not know if it is improvement in insomniathat causes the improvement in cortisol recovery or if the improvement
in cortisol recovery causes improved sleep. An alternative explanation
would be that through the ACT treatment, the patients learned more
adaptive skills for coping with stress. This could lead to both improve-
ments in insomnia and to improved cortisol recovery.
Limitations
Amajor limitation of the current study is that we used self-report on
the Chalder Fatigue Scale as a marker for CFS and not a clinical diagnos-
tic assessment. Thus, the group of patients here reported were on sick
leave and had self-reported severe fatigue of at least 6months duration,
but this groupmay not be generalizable to the group that meets the full
criteria for CFS. Similarly, we used self-reported levels of insomnia on
the Insomnia Severity Index (ISI) as a marker for levels of insomnia se-
verity and not a clinical assessment of insomnia. However, the ISI is
widely used in insomnia research and recommended as a standard
questionnaire to assess insomnia severity and insomnia change during
treatment (31).
Second,we did not include sleep diary data or actigraphydatawhere
we can test if circadian factors have an impact on the results. Similarly,
we did not have any objective measure of sleep to screen for organic
sleep disorders. It is therefore possible that some of the patients who re-
port high on insomnia severity could have sleep apnea or related sleep
disorders. It is unlikely that these patients would have improved sleep
quality over the duration of this intervention.
A third limitation was that the TSST was administered to a subgroup
of our sample and not the entire sample. This limits the generalizability
of our ﬁndings, though the sample was randomly selected and the sam-
ple size is similar to other studies using the TSST (e.g. (32)).
Fourth, not all patients were drug-free and medication could have
had an effect on cortisol secretion in the TSST. However, a previous
study from the same patient sample has found that neither the use of
anti-depressive medication nor the use of beta-blockers had an effect
on cortisol slope on the TSST (17).
Conclusion
We found that improvement in insomnia severity had a signiﬁcant
impact on improvement in fatigue that was independent of improve-
ments in pain, depression and anxiety. Moreover, we found that im-
provement in insomnia severity was also associated with improved
ability to recover after a stressful situation during the day. Insomnia se-
verity may be a maintaining factor in chronic fatigue and speciﬁcally
targeting this in treatment could increase treatment response.
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